-
Glucagon/GLP-1 receptor dual agonist demonstrates efficacy for obesity and MASLD
Matthias H. Tschöp, MD, and other researchers detailed phase 3 results of SYNCHRONIZE-1 and SYNCHRONIZE-MASLD showing that survodutide leads to significant weight loss, reduction in liver fat, and other health improvements.